SarCNU

N/A

Report date: 2022/03/23 14:30:18
NME

Base Information

Drug NameSarCNU
Drug Alias NameSarNU2-chloroethyl-3-sarcosinamide-1-nitrosoureaNSC-364432
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAlkylating agentsDNA inhibitors
TargetsDNA
Therapy Area/IndicationsCNS Embryonal TumorSolid tumoursColorectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNcic Clinical Trials Group
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteNcic Clinical Trials Group
Active IndicationsN/A
Inactive IndicationsCNS Embryonal TumorSolid tumoursColorectal Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A